— Know what they know.
Not Investment Advice

NATCOPHARM.NS NSE

Natco Pharma Limited
1W: -1.7% 1M: -3.3% 3M: -11.8% YTD: -2.9% 1Y: -9.0% 3Y: -6.2% 5Y: -13.2%
₹819.00 ($8.50)
-8.50 (-1.03%)
 
NSE · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Sell · Power 35 · ₹146.7B mcap · 84M float · 0.756% daily turnover

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

B
Oct 01, 2026
DCF
5
ROE
4
ROA
1
D/E
1
P/E
3
P/B
3
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. NATCOPHARM.NS receives an overall rating of B. Strongest factors: DCF (5/5), ROE (4/5). Areas of concern: ROA (1/5), D/E (1/5).
Rating Change History
DateFromTo
2026-08-31 C B
2026-08-17 A C
2026-06-01 C+ A
2026-05-18 C C+
2026-05-15 C+ C
2026-05-14 C C+
2026-05-11 C+ C
2026-04-22 C C+
2026-04-09 C+ C
2026-02-18 A C+

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

★ ★ ★ ★ ★ 67 Grade A+
Profitability
74
Balance Sheet
98
Earnings Quality
57
Growth
16
Value
81
Momentum
50
Safety
100
Cash Flow
97
The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. NATCOPHARM.NS scores highest in Safety (100/100) and lowest in Growth (16/100). An overall grade of A+ places NATCOPHARM.NS among the highest-quality companies in its peer group.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
7.80
Safe Zone
Piotroski F-Score
5/9
✓ ✓ ✗ ✓ ✗ ✗ ✓ ✓ ✗
Beneish M-Score
-1.87
Unlikely Manipulator
Ohlson O-Score
-13.75
Bankruptcy prob: 0.0%
Low Risk
Credit Rating
AA+
Score: 94.7/100
Trend: Stable
Earnings Quality
75/100
OCF/NI: 1.75x
Accruals: -10.8%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. NATCOPHARM.NS scores 7.80, placing it in the Safe Zone (safe > 2.99, distress < 1.81). Bankruptcy is statistically unlikely within the next two years. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. NATCOPHARM.NS scores 5/9, indicating moderate financial health — some areas of strength offset by weaknesses in others. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. NATCOPHARM.NS's score of -1.87 falls below this threshold, suggesting earnings are unlikely to be manipulated. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. NATCOPHARM.NS's implied 0.0% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. NATCOPHARM.NS receives an estimated rating of AA+ (score: 94.7/100), with a stable trend. The Earnings Quality score measures how well reported earnings are backed by real cash. It evaluates the operating cash flow to net income ratio (OCF/NI ≥ 1.0 means every dollar of earnings is cash-backed) and the accruals ratio (the gap between earnings and cash flow relative to assets — lower is better). NATCOPHARM.NS's score of 75/100 is high — cash flows strongly support reported earnings.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
12.82x
PEG
-0.39x
P/S
4.21x
P/B
1.59x
P/FCF
8.43x
P/OCF
7.03x
EV/EBITDA
9.24x
EV/Revenue
3.93x
EV/EBIT
10.49x
EV/FCF
7.75x
Earnings Yield
8.13%
FCF Yield
11.86%
Shareholder Yield
0.65%
Graham Number
$957.98
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. At 12.8x earnings, NATCOPHARM.NS trades at a reasonable valuation. An earnings yield of 8.1% exceeds typical risk-free rates, suggesting equities are being compensated for risk. Graham's intrinsic value formula yields $957.98 per share, suggesting a potential 17% margin of safety at the current price.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
0.929
NI / EBT
×
Interest Burden
0.999
EBT / EBIT
×
EBIT Margin
0.375
EBIT / Rev
×
Asset Turnover
0.414
Rev / Assets
×
Equity Multiplier
1.171
Assets / Equity
=
ROE
16.9%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. NATCOPHARM.NS's ROE of 16.9% is driven by Asset Turnover (0.414), indicating efficient use of assets to generate revenue. A tax burden ratio of 0.93 indicates minimal tax leakage — the company retains over 90% of pre-tax earnings.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Two adjustments we make, and why. Growth is capped at 15%. Graham defined g as expected growth over the next seven to ten years, not last year's rate. Across US companies since 1994 the median realized 7-year EPS growth is 5–8% regardless of how fast a company grew beforehand, and of 4,457 company-quarters that grew faster than 200%, none sustained it. Uncapped, the formula assigned fair multiples in the hundreds to companies that had never held that rate — and scored worse than simply reading the P/E. Capped, it carries real information. The verdict has three states, not two. Tested over 377,249 stock-months, this ratio only separates outcomes at its extremes: below 0.25 beat the universe by 1.3 points a year, above 3.0 lagged by 2.7, and everything in between sat inside a one-point band. Rather than call two-thirds of the market "undervalued" on a threshold of 1.0, we say Neutral where the model cannot tell — which is most of the time.

Adj. Growth Rate
15.00%
Fair P/E
38.50x
Intrinsic Value
$3049.64
Price/Value
0.32x
Margin of Safety
68.06%
Premium
-68.06%
Assessment
Neutral
Graham's classic formula uses analyst-projected growth to estimate a fair P/E (8.5 + 2g). Our adjusted version replaces that projection with NATCOPHARM.NS's realized 15.0% 3-year EPS CAGR, capped at 15% — demonstrated performance rather than forecasts, held to a rate companies have historically sustained. NATCOPHARM.NS actually compounded EPS at 26.4% over three years; the model uses 15%, the highest rate it will extrapolate — of 4,457 company-quarters that grew faster than 200%, none sustained it over the following seven years. NATCOPHARM.NS trades at a -68% premium to its adjusted intrinsic value of $3049.64, suggesting the market is pricing in future growth beyond what historical earnings support. The adjusted fair P/E of 38.5x compares to the current market P/E of 12.8x.

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$821.30
Median 1Y
$828.34
5th Pctile
$486.15
95th Pctile
$1408.27
Ann. Volatility
33.8%
25th–75th percentile 5th–95th percentile Median path Historical
All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
ROE 10.0% 6.2% 6.6% 4.1% 9.9% 9.3% 8.8% 15.7% 17.8% 22.9% 25.9% 25.9% 30.5% 31.3% 30.0% 28.0% 25.2% 19.5% 19.7% 16.9% 16.86%
ROA 8.4% 5.0% 5.4% 3.4% 8.4% 8.0% 7.7% 13.3% 15.1% 19.9% 22.6% 22.1% 26.1% 26.8% 25.7% 24.3% 21.9% 16.5% 16.7% 14.4% 14.40%
ROIC 18.6% 12.0% 16.3% 14.8% 23.0% 25.2% 22.8% 31.5% 35.8% 41.9% 45.9% 48.3% 52.5% 53.6% 49.7% 45.8% 37.8% 33.6% 31.4% 14.5% 14.53%
ROCE 10.0% 4.9% 5.2% 2.8% 9.8% 9.6% 9.6% 16.3% 19.3% 24.6% 27.5% 27.3% 31.1% 30.3% 27.1% 25.6% 23.2% 18.9% 20.9% 16.3% 16.26%
Gross Margin 80.7% 75.5% 83.4% 46.5% 83.3% 75.5% 76.6% 68.3% 82.8% 79.1% 78.6% 83.7% 86.8% 87.0% 82.6% 76.6% 82.5% 87.5% 79.4% 79.1% 79.07%
Operating Margin 54.4% 46.5% 62.3% -9.2% 69.4% 50.0% 55.1% 43.4% 70.7% 67.2% 62.5% 58.1% 76.4% 76.0% 52.7% 54.6% 38.6% 38.7% 17.4% 10.4% 10.45%
Net Margin 18.3% 17.3% 14.3% -8.4% 36.2% 13.1% 12.6% 30.7% 36.9% 35.8% 28.0% 36.1% 49.1% 49.4% 28.0% 33.2% 36.2% 38.0% 23.4% 36.2% 36.25%
EBITDA Margin 25.6% 18.6% 16.8% -3.4% 47.5% 21.8% 20.0% 38.5% 50.5% 44.4% 34.7% 46.0% 59.3% 58.6% 7.8% 40.8% 47.6% 49.8% 33.5% 27.8% 27.79%
FCF Margin 2.8% 3.3% 2.7% 1.8% -1.0% 1.9% 5.0% 7.4% 11.3% 9.5% 9.0% 12.0% 14.5% 16.3% 20.4% 22.8% 26.1% 44.2% 45.6% 50.7% 50.72%
OCF Margin 15.6% 18.0% 14.1% 11.6% 6.7% 6.9% 7.5% 9.6% 11.3% 9.5% 9.0% 14.1% 18.5% 21.8% 28.3% 30.1% 33.1% 53.3% 54.0% 60.8% 60.84%
ROE 3Y Avg snapshot only 21.30%
ROE 5Y Avg snapshot only 16.51%
ROA 3Y Avg snapshot only 18.25%
ROIC 3Y Avg snapshot only 25.56%
ROIC Economic snapshot only 11.51%
Cash ROA snapshot only 22.41%
Cash ROIC snapshot only 31.78%
CROIC snapshot only 26.50%
NOPAT Margin snapshot only 27.81%
Pretax Margin snapshot only 37.43%
R&D / Revenue snapshot only 0.00%
SGA / Revenue snapshot only 0.00%
SBC / Revenue snapshot only 0.00%
Valuation
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
P/E Ratio 50.76 61.68 58.69 78.93 27.80 26.60 25.85 14.12 15.09 13.74 11.27 12.20 12.68 13.01 13.26 7.57 9.75 9.26 10.39 12.30 12.819
P/S Ratio 10.49 10.67 9.54 6.89 4.77 4.37 4.18 3.73 4.15 4.35 3.76 4.23 4.91 5.55 5.78 3.22 3.76 3.25 3.54 4.28 4.210
P/B Ratio 4.84 3.73 3.80 3.15 2.71 2.37 2.20 2.07 2.52 2.93 2.72 2.89 3.55 3.54 3.46 1.88 2.18 1.65 1.87 1.89 1.591
P/FCF 376.51 319.54 350.86 379.60 -466.57 227.48 84.11 50.66 36.68 45.65 41.81 35.24 33.93 34.08 28.36 14.12 14.40 7.34 7.77 8.43 8.434
P/OCF 67.43 59.24 67.82 59.30 70.75 62.98 55.79 38.84 36.68 45.65 41.81 29.95 26.56 25.38 20.41 10.71 11.39 6.09 6.57 7.03 7.032
EV/EBITDA 36.22 46.56 45.03 52.50 19.87 16.83 15.40 9.54 10.18 9.81 8.18 8.68 9.58 9.74 10.50 5.61 7.27 5.65 6.09 9.24 9.244
EV/Revenue 10.21 10.40 9.30 6.73 4.64 4.00 3.80 3.38 3.83 4.07 3.51 3.88 4.58 5.05 5.25 2.72 3.26 2.38 2.71 3.93 3.931
EV/EBIT 45.57 71.75 68.82 106.08 25.96 22.02 20.37 11.30 11.82 10.99 9.08 9.59 10.48 10.52 11.48 6.13 8.05 6.33 6.76 10.49 10.495
EV/FCF 366.44 311.39 342.07 370.32 -453.32 208.17 76.42 45.90 33.85 42.80 39.00 32.34 31.65 31.04 25.77 11.92 12.47 5.37 5.94 7.75 7.750
Earnings Yield 2.0% 1.6% 1.7% 1.3% 3.6% 3.8% 3.9% 7.1% 6.6% 7.3% 8.9% 8.2% 7.9% 7.7% 7.5% 13.2% 10.3% 10.8% 9.6% 8.1% 8.13%
FCF Yield 0.3% 0.3% 0.3% 0.3% -0.2% 0.4% 1.2% 2.0% 2.7% 2.2% 2.4% 2.8% 2.9% 2.9% 3.5% 7.1% 6.9% 13.6% 12.9% 11.9% 11.86%
Price/Tangible Book snapshot only 1.946
EV/OCF snapshot only 6.461
EV/Gross Profit snapshot only 4.732
Acquirers Multiple snapshot only 13.034
Shareholder Yield snapshot only 0.65%
Graham Number snapshot only $957.98
Leverage & Solvency
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Current Ratio 4.45 3.84 3.84 3.52 3.52 6.00 6.00 4.39 4.39 3.81 3.81 4.14 4.14 4.96 4.96 5.59 5.59 4.10 4.10 3.01 3.006
Quick Ratio 2.71 2.45 2.45 2.30 2.30 4.13 4.13 3.21 3.21 3.01 3.01 3.32 3.32 4.19 4.19 4.77 4.77 3.62 3.62 2.47 2.465
Debt/Equity 0.07 0.09 0.09 0.10 0.10 0.02 0.02 0.04 0.04 0.05 0.05 0.07 0.07 0.03 0.03 0.04 0.04 0.03 0.03 0.08 0.077
Net Debt/Equity -0.13 -0.10 -0.10 -0.08 -0.08 -0.20 -0.20 -0.19 -0.19 -0.18 -0.18 -0.24 -0.24 -0.32 -0.32 -0.29 -0.29 -0.44 -0.44 -0.15 -0.153
Debt/Assets 0.06 0.07 0.07 0.08 0.08 0.02 0.02 0.03 0.03 0.04 0.04 0.06 0.06 0.03 0.03 0.03 0.03 0.02 0.02 0.06 0.064
Debt/EBITDA 0.53 1.12 1.07 1.73 0.77 0.15 0.14 0.18 0.16 0.17 0.15 0.22 0.19 0.09 0.10 0.13 0.14 0.14 0.13 0.41 0.412
Net Debt/EBITDA -1.00 -1.22 -1.16 -1.32 -0.58 -1.56 -1.55 -0.99 -0.85 -0.65 -0.59 -0.78 -0.69 -0.95 -1.05 -1.03 -1.12 -2.06 -1.88 -0.82 -0.816
Interest Coverage 36.74 16.61 15.68 6.97 21.72 22.84 24.25 55.85 66.24 88.68 94.32 84.46 91.43 109.00 98.43 82.27 81.31 53.36 50.77 41.62 41.621
Equity Multiplier 1.16 1.19 1.19 1.20 1.20 1.11 1.11 1.16 1.16 1.18 1.18 1.18 1.18 1.15 1.15 1.13 1.13 1.21 1.21 1.20 1.201
Cash Ratio snapshot only 1.267
Debt Service Coverage snapshot only 47.251
Cash to Debt snapshot only 2.982
FCF to Debt snapshot only 2.897
Defensive Interval snapshot only 510.8 days
Efficiency & Turnover
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Asset Turnover 0.41 0.29 0.33 0.39 0.49 0.49 0.48 0.50 0.55 0.63 0.68 0.64 0.67 0.63 0.59 0.57 0.57 0.47 0.49 0.41 0.414
Inventory Turnover 0.59 0.42 0.43 0.66 0.74 0.80 0.83 0.78 0.84 1.11 1.18 0.94 0.92 0.94 0.83 0.93 1.00 0.97 1.03 0.82 0.825
Receivables Turnover 3.95 2.67 3.04 3.77 4.68 5.92 5.75 3.67 4.01 4.78 5.14 3.91 4.13 3.57 3.35 3.64 3.61 2.78 2.89 3.83 3.833
Payables Turnover 2.15 1.48 1.52 3.80 4.24 4.50 4.65 3.08 3.30 3.19 3.37 3.00 2.94 2.04 1.81 2.85 3.06 1.87 1.99 2.02 2.018
DSO 92 137 120 97 78 62 63 100 91 76 71 93 88 102 109 100 101 131 126 95 95.2 days
DIO 620 878 852 553 495 456 441 466 434 328 310 390 399 390 440 391 364 376 353 443 442.5 days
DPO 170 247 240 96 86 81 79 119 111 114 108 122 124 179 202 128 119 195 183 181 180.8 days
Cash Conversion Cycle 543 768 733 554 487 436 426 447 414 290 273 362 363 313 347 363 346 312 296 357 356.9 days
Fixed Asset Turnover snapshot only 1.436
Operating Cycle snapshot only 537.7 days
Cash Velocity snapshot only 1.916
Capital Intensity snapshot only 2.715
Growth (YoY)
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Revenue -4.2% -35.8% -22.6% -5.3% 27.2% 67.5% 43.0% 39.2% 22.5% 44.0% 59.1% 47.8% 42.5% 28.1% 11.8% 10.7% 4.1% -3.8% 6.6% -8.0% -7.98%
Net Income -10.7% -51.2% -43.3% -61.4% 5.7% 59.1% 42.2% 3.2% 96.2% 1.8% 2.3% 94.1% 1.0% 72.5% 46.0% 35.8% 3.7% -20.9% -16.5% -24.8% -24.76%
EPS -10.7% -51.1% -43.2% -61.3% 5.6% 58.9% 42.3% 3.2% 98.3% 1.8% 2.4% 97.7% 1.0% 72.5% 46.0% 35.8% 3.7% -20.9% -16.5% -24.7% -24.75%
FCF -44.7% -15.9% -22.1% -37.6% -1.5% -3.6% 1.6% 4.6% 14.6% 6.1% 1.9% 1.4% 82.4% 1.2% 1.5% 1.1% 88.0% 1.6% 1.4% 1.0% 1.05%
EBITDA -2.5% -52.3% -46.2% -58.4% 5.3% 78.3% 70.7% 2.8% 97.6% 1.5% 1.8% 86.6% 81.2% 60.0% 30.2% 19.9% -2.4% -21.9% -5.2% -19.2% -19.24%
Op. Income 2.5% -47.6% -21.8% -25.6% 25.3% 1.0% 42.3% 1.2% 55.3% 92.2% 1.3% 74.1% 68.1% 47.1% 25.0% 15.6% -12.6% -38.4% -38.4% -59.0% -59.01%
OCF Growth snapshot only 86.14%
Asset Growth snapshot only 28.30%
Equity Growth snapshot only 21.22%
Debt Growth snapshot only 1.56%
Shares Change snapshot only -0.02%
Dividend Growth snapshot only -27.33%
Growth (CAGR)
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Revenue 3Y -6.1% -15.1% -11.2% -2.4% 5.7% 7.5% 7.9% 12.3% 14.3% 15.7% 20.7% 24.9% 30.4% 45.6% 36.5% 31.6% 22.0% 21.0% 23.8% 14.6% 14.62%
Revenue 5Y 10.7% 1.5% -1.0% -0.5% 2.9% 3.7% 4.3% 4.4% 5.2% 8.1% 9.7% 13.8% 15.6% 18.1% 17.4% 18.3% 17.2% 13.8% 16.0% 14.7% 14.68%
EPS 3Y -20.2% -33.5% -30.5% -35.7% -11.9% -9.2% -7.3% 15.8% 23.2% 29.9% 39.4% 47.5% 61.9% 97.8% 90.9% 1.2% 60.9% 56.8% 59.8% 26.4% 26.44%
EPS 5Y 16.3% 3.0% -6.8% -19.6% -6.4% -6.6% -8.0% 0.8% 1.3% 5.7% 9.9% 17.2% 22.4% 29.5% 31.3% 33.0% 31.5% 24.5% 27.0% 26.8% 26.84%
Net Income 3Y -20.5% -33.8% -30.7% -35.9% -11.8% -9.1% -7.2% 15.8% 22.8% 29.1% 38.4% 46.6% 60.9% 96.6% 89.6% 1.2% 59.9% 55.8% 58.8% 25.6% 25.64%
Net Income 5Y 17.4% 3.7% -5.9% -18.9% -4.8% -5.9% -7.5% 0.5% 0.8% 5.0% 9.2% 16.6% 22.0% 29.1% 30.8% 32.5% 31.0% 24.1% 26.4% 26.3% 26.33%
EBITDA 3Y -18.8% -33.0% -30.1% -31.8% -9.3% -4.5% -0.1% 18.9% 26.6% 28.8% 36.5% 44.0% 55.6% 92.8% 83.3% 1.0% 51.7% 46.4% 50.7% 21.8% 21.81%
EBITDA 5Y 13.1% -0.4% -8.3% -18.3% -5.4% -5.0% -5.4% 0.8% 2.2% 6.1% 10.0% 17.9% 21.7% 28.5% 29.2% 30.3% 29.1% 21.7% 25.7% 23.7% 23.69%
Gross Profit 3Y -7.4% -16.9% -11.8% -7.4% 1.8% 4.3% 3.8% 10.8% 15.3% 17.0% 22.9% 28.8% 33.4% 49.9% 39.7% 39.6% 27.0% 26.0% 29.6% 18.1% 18.15%
Gross Profit 5Y 11.2% 3.6% 1.5% 0.1% 4.2% 4.2% 2.8% 3.6% 4.1% 6.6% 8.7% 13.7% 15.8% 19.4% 19.0% 19.7% 19.6% 16.1% 18.5% 17.3% 17.32%
Op. Income 3Y -13.4% -27.9% -19.9% -13.7% 1.4% 5.9% 5.9% 19.4% 25.9% 26.7% 36.0% 40.7% 48.5% 78.7% 59.0% 63.0% 31.6% 20.3% 20.3% -6.2% -6.23%
Op. Income 5Y 11.7% -2.6% -6.1% -6.5% 0.8% 1.2% -0.2% 4.0% 4.8% 7.8% 10.6% 19.2% 22.2% 27.4% 27.4% 27.9% 24.0% 13.0% 14.1% 5.7% 5.72%
FCF 3Y 19.2% 7.9% -17.4% -34.0% — -38.7% -11.1% 14.5% 51.8% 79.4% 80.4% 1.0% 1.3% 1.5% 1.7% 2.1% — 2.4% 1.6% 1.2% 1.18%
FCF 5Y — — — 5.5% — -1.6% 21.7% 39.3% 60.7% 53.9% 33.5% 31.3% 29.9% 29.1% 38.7% 50.1% 64.4% 1.0% 1.0% 1.1% 1.05%
OCF 3Y -5.4% -16.9% -22.8% -26.3% -35.8% -36.4% -33.2% -21.8% -11.3% -6.7% -6.2% 20.2% 38.2% 55.3% 72.3% 80.6% 1.1% 1.4% 1.4% 1.1% 1.12%
OCF 5Y 24.2% 25.8% 10.3% 1.9% -9.4% -8.0% -9.1% -4.1% -0.8% -6.1% -7.7% -0.0% 4.8% 8.3% 14.9% 19.7% 24.8% 41.2% 42.6% 50.1% 50.11%
Assets 3Y 8.9% 5.6% 5.6% 5.9% 5.9% 4.4% 4.4% 7.2% 7.2% 7.0% 7.0% 13.0% 13.0% 17.7% 17.7% 19.1% 19.1% 27.1% 27.1% 25.1% 25.09%
Assets 5Y 21.3% 19.5% 19.5% 17.1% 17.1% 16.4% 16.4% 8.8% 8.8% 7.8% 7.8% 9.9% 9.9% 13.1% 13.1% 13.5% 13.5% 15.4% 15.4% 18.2% 18.24%
Equity 3Y 10.3% 7.4% 7.4% 6.9% 6.9% 7.4% 7.4% 8.9% 8.9% 9.2% 9.2% 12.4% 12.4% 19.1% 19.1% 21.3% 21.3% 23.7% 23.7% 23.7% 23.68%
Book Value 3Y 10.8% 7.9% 7.8% 7.2% 6.9% 7.4% 7.4% 8.9% 9.3% 9.9% 10.0% 13.1% 13.1% 19.8% 20.0% 22.0% 22.1% 24.5% 24.5% 24.5% 24.47%
Dividend 3Y -9.3% -14.3% -17.5% -9.3% -9.7% -19.9% -37.8% -37.8% — — — 28.5% — — — 54.6% 18.5% 1.9% -11.2% -9.5% -9.53%
Growth Quality
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Revenue Stability 0.34 0.03 0.01 0.06 0.10 0.01 0.13 0.18 0.30 0.19 0.27 0.56 0.71 0.71 0.75 0.83 0.90 0.84 0.89 0.84 0.835
Earnings Stability 0.03 0.00 0.10 0.53 0.48 0.46 0.54 0.12 0.02 0.01 0.07 0.30 0.50 0.57 0.63 0.73 0.82 0.73 0.76 0.75 0.747
Margin Stability 0.96 0.94 0.94 0.92 0.93 0.95 0.95 0.95 0.96 0.95 0.95 0.93 0.95 0.95 0.93 0.93 0.94 0.94 0.92 0.95 0.946
Rev. Growth Consistency 0.00 0.00 0.00 0.00 0.50 0.50 0.50 0.50 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.00 1.00 0.00 0.000
Earn. Growth Consistency 0.00 0.00 0.00 0.00 0.50 0.50 0.50 0.50 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.00 0.00 0.00 0.000
FCF Positive Streak 1 1 1 1 0 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1
Earnings Persistence 0.96 0.50 0.83 0.50 0.98 0.50 0.83 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.82 0.86 0.99 0.92 0.93 0.90 0.901
Earnings Smoothness 0.89 0.31 0.45 0.11 0.94 0.54 0.65 0.00 0.35 0.06 0.00 0.36 0.33 0.47 0.63 0.70 0.96 0.77 0.82 0.72 0.717
ROE Trend -0.05 -0.08 -0.06 -0.07 -0.01 -0.01 -0.01 0.07 0.07 0.14 0.17 0.14 0.15 0.12 0.10 0.06 -0.00 -0.06 -0.07 -0.09 -0.089
Gross Margin Trend -0.01 0.00 0.03 -0.07 -0.03 -0.03 -0.05 0.04 0.01 0.02 0.02 0.08 0.08 0.10 0.11 0.05 0.03 0.01 0.00 0.01 0.006
FCF Margin Trend -0.04 -0.03 -0.03 -0.03 -0.05 -0.01 0.02 0.05 0.10 0.07 0.05 0.07 0.09 0.11 0.13 0.13 0.13 0.31 0.31 0.33 0.333
Sustainable Growth Rate 7.3% 3.9% 4.5% 2.0% 8.1% 8.1% 8.4% 15.2% 17.8% 22.9% 25.9% 25.1% 28.9% 29.2% 27.2% 25.7% 23.2% 17.8% 18.2% 15.5% 15.52%
Internal Growth Rate 6.5% 3.3% 3.8% 1.7% 7.3% 7.6% 7.8% 14.8% 17.8% 24.8% 29.1% 27.3% 32.8% 33.4% 30.5% 28.7% 25.1% 17.7% 18.2% 15.3% 15.28%
Cash Flow Quality
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
OCF/Net Income 0.75 1.04 0.87 1.33 0.39 0.42 0.46 0.36 0.41 0.30 0.27 0.41 0.48 0.51 0.65 0.71 0.86 1.52 1.58 1.75 1.749
FCF/OCF 0.18 0.19 0.19 0.16 -0.15 0.28 0.66 0.77 1.00 1.00 1.00 0.85 0.78 0.74 0.72 0.76 0.79 0.83 0.84 0.83 0.834
FCF/Net Income snapshot only 1.458
OCF/EBITDA snapshot only 1.431
CapEx/Revenue 12.8% 14.7% 11.3% 9.8% 7.8% 5.0% 2.5% 2.2% 0.0% 0.0% 0.0% 2.1% 4.0% 5.6% 7.9% 8.0% 8.4% 10.6% 10.5% 11.7% 11.74%
CapEx/Depreciation snapshot only 2.317
Accruals Ratio 0.02 -0.00 0.01 -0.01 0.05 0.05 0.04 0.08 0.09 0.14 0.16 0.13 0.14 0.13 0.09 0.07 0.03 -0.09 -0.10 -0.11 -0.108
Sloan Accruals snapshot only -0.118
Cash Flow Adequacy snapshot only 4.195
Earnings Quality Score snapshot only 0.750
Dividends & Buybacks
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Dividend Yield 0.5% 0.6% 0.5% 0.6% 0.7% 0.5% 0.2% 0.2% 0.0% 0.0% 0.0% 0.3% 0.4% 0.5% 0.7% 1.1% 0.8% 0.9% 0.7% 0.6% 0.55%
Dividend/Share $5.77 $5.23 $4.68 $4.69 $4.25 $2.68 $1.12 $1.13 $0.00 $0.00 $0.00 $2.38 $4.77 $7.15 $9.54 $8.66 $7.78 $7.41 $6.54 $6.29 $4.49
Payout Ratio 26.8% 37.3% 31.2% 50.2% 18.7% 12.0% 5.3% 2.9% 0.0% 0.0% 0.0% 3.1% 5.2% 6.6% 9.2% 8.2% 8.2% 8.6% 7.5% 7.9% 7.94%
FCF Payout Ratio 2.0% 1.9% 1.9% 2.4% — 1.0% 17.2% 10.3% 0.0% 0.0% 0.0% 8.9% 14.0% 17.3% 19.6% 15.3% 12.1% 6.8% 5.6% 5.4% 5.45%
Total Payout Ratio 38.7% 42.5% 31.2% 50.2% 18.7% 12.0% 5.3% 2.9% 0.0% 0.0% 0.0% 7.6% 13.0% 16.4% 22.8% 18.3% 15.7% 12.8% 7.5% 7.9% 7.94%
Div. Increase Streak 0 0 0 0 0 0 0 0 — — — 0 0 0 0 1 1 1 0 0 0
Chowder Number -0.26 -0.37 -0.44 -0.25 -0.26 -0.48 -0.76 -0.76 — — — 1.08 — — — 2.64 0.64 0.05 -0.31 -0.27 -0.267
Buyback Yield 0.2% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.4% 0.6% 0.8% 1.0% 1.3% 0.8% 0.4% 0.0% 0.0% 0.00%
Net Buyback Yield 0.2% 0.0% -0.0% -0.0% -0.0% -0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.4% 0.6% 0.8% 1.0% 1.3% 0.7% 0.4% -0.0% -0.0% -0.02%
Total Shareholder Return 0.7% 0.6% 0.5% 0.6% 0.7% 0.5% 0.2% 0.2% 0.0% 0.0% 0.0% 0.6% 1.0% 1.3% 1.7% 2.4% 1.6% 1.4% 0.7% 0.6% 0.62%
DuPont Factors
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Tax Burden (NI/EBT) 0.77 0.82 0.85 0.84 0.84 0.82 0.80 0.83 0.84 0.84 0.84 0.83 0.83 0.83 0.82 0.82 0.82 0.83 0.84 0.93 0.929
Interest Burden (EBT/EBIT) 1.20 1.45 1.42 1.64 1.15 1.11 1.09 1.06 1.02 1.02 1.03 1.03 1.07 1.08 1.16 1.17 1.16 1.13 1.01 1.00 0.999
EBIT Margin 0.22 0.14 0.14 0.06 0.18 0.18 0.19 0.30 0.32 0.37 0.39 0.41 0.44 0.48 0.46 0.44 0.40 0.38 0.40 0.37 0.375
Asset Turnover 0.41 0.29 0.33 0.39 0.49 0.49 0.48 0.50 0.55 0.63 0.68 0.64 0.67 0.63 0.59 0.57 0.57 0.47 0.49 0.41 0.414
Equity Multiplier 1.19 1.22 1.22 1.18 1.18 1.15 1.15 1.18 1.18 1.15 1.15 1.17 1.17 1.17 1.17 1.15 1.15 1.18 1.18 1.17 1.171
Per Share
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
EPS (Diluted TTM) $21.54 $14.03 $14.97 $9.32 $22.75 $22.29 $21.29 $39.19 $45.11 $62.94 $71.37 $77.48 $91.36 $108.57 $104.19 $105.26 $94.79 $85.90 $86.96 $79.21 $79.21
Book Value/Share $225.86 $231.90 $231.42 $233.86 $233.54 $250.29 $250.21 $267.02 $269.72 $295.52 $295.66 $326.67 $326.76 $399.14 $399.43 $424.69 $424.74 $482.88 $483.02 $514.92 $514.83
Tangible Book/Share $225.35 $231.25 $230.78 $226.58 $226.26 $239.83 $239.75 $256.73 $259.33 $284.44 $284.58 $315.89 $315.98 $385.88 $386.15 $409.83 $409.88 $468.35 $468.49 $500.55 $500.55
Revenue/Share $104.28 $81.05 $92.12 $106.75 $132.58 $135.54 $131.77 $148.39 $164.05 $198.95 $213.91 $223.36 $235.82 $254.77 $239.10 $247.43 $245.58 $245.08 $254.78 $227.74 $194.55
FCF/Share $2.90 $2.71 $2.50 $1.94 $-1.36 $2.61 $6.54 $10.92 $18.56 $18.94 $19.25 $26.83 $34.15 $41.45 $48.73 $56.45 $64.22 $108.43 $116.22 $115.51 $56.40
OCF/Share $16.22 $14.60 $12.95 $12.41 $8.94 $9.41 $9.86 $14.25 $18.56 $18.94 $19.25 $31.56 $43.62 $55.66 $67.69 $74.41 $81.20 $130.74 $137.55 $138.55 $66.47
Cash/Share $44.81 $42.40 $42.31 $41.68 $41.62 $55.01 $54.99 $61.62 $62.25 $67.86 $67.90 $99.24 $99.27 $137.52 $137.62 $139.39 $139.41 $227.59 $227.65 $118.89 $0.00
EBITDA/Share $29.39 $18.11 $19.02 $13.68 $30.92 $32.24 $32.47 $52.57 $61.73 $82.58 $91.81 $99.92 $112.84 $132.13 $119.58 $119.88 $110.14 $103.19 $113.27 $96.84 $96.84
Debt/Share $15.56 $20.35 $20.31 $23.70 $23.66 $4.69 $4.69 $9.65 $9.75 $13.82 $13.82 $21.55 $21.55 $11.63 $11.64 $15.60 $15.60 $14.55 $14.56 $39.87 $39.87
Net Debt/Share $-29.25 $-22.05 $-22.01 $-17.99 $-17.96 $-50.32 $-50.30 $-51.98 $-52.50 $-54.05 $-54.07 $-77.69 $-77.71 $-125.88 $-125.97 $-123.79 $-123.81 $-213.04 $-213.10 $-79.03 $-79.03
Academic Models
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Altman Z-Score — — — — — — — — — — — — — — — — — — — — 7.798
Altman Z-Prime snapshot only 15.046
Piotroski F-Score 5 6 6 4 5 7 7 7 7 6 6 6 6 7 7 6 5 6 4 5 5
Beneish M-Score -2.62 -2.61 -2.43 -1.49 -1.34 -2.25 -2.30 -1.81 -1.73 -0.18 -0.24 -1.60 -1.49 -1.65 -1.59 -1.95 -1.99 -2.48 -2.47 -1.87 -1.874
Ohlson O-Score snapshot only -13.752
ROIC (Greenblatt) snapshot only 24.60%
Net-Net WC snapshot only $178.68
EVA snapshot only $3535123517.85
Credit
Metric Trend Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Current
Credit Rating snapshot only AA+
Credit Score 95.32 91.39 91.45 83.73 90.94 95.64 96.20 80.07 80.42 95.34 95.06 95.24 95.36 94.99 95.19 94.83 94.80 94.62 94.61 94.68 94.677
Credit Grade snapshot only 2
Credit Trend snapshot only -0.157
Implied Spread (bps) snapshot only 65.000
Industry Credit Rank snapshot only 85
Sector Credit Rank snapshot only 91

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms